GET DAILY SIGNALSPhio Pharmaceuticals (PHIO) Reports Wider Q3 Loss as R&D Spending Rises
Key Takeaways
- Phio Pharmaceuticals reported a net loss of $4.2 million for the third quarter of 2026, up from $2.4 million in the same period a year earlier.
- Net loss per share came in at $0.36, matching the Wall Street consensus estimate of $0.36.
- Research and development (R&D) expenses rose 159% year over year to $3.0 million as the company advanced its lead drug candidate, PH-762.
- Cash and cash equivalents declined to $10.6 million as of September 30, 2026, from $21.0 million at the end of 2025.
- The company is awaiting a U.S. Food and Drug Administration (FDA) response by the end of November 2026, with a Phase 2b study expected to begin in the first quarter of 2027.
- Revenue remained $0, consistent with Phio's status as a pre-revenue, clinical-stage biotechnology company.
- For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated pages linked here.
- Discover automated trading ideas by exploring Trending AI Robots.
Why These Results Matter
As a clinical-stage biopharmaceutical company, PHIO does not yet generate product revenue, so investors focus less on the top line and more on cash management, pipeline progress, and regulatory milestones. The third-quarter report arrives at a pivotal moment: the company has completed its Phase 1b trial for PH-762, its lead INTASYL® gene-silencing candidate for skin cancers, and is transitioning toward a larger Phase 2b study. Rising R&D spending reflects this acceleration, while a shrinking cash balance highlights the financing runway questions that typically dominate sentiment for early-stage developers. How PHIO balances clinical momentum against capital preservation is the central theme of this quarterly update. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter's Financial Details
PHIO reported a net loss of $4.2 million for the quarter ended September 30, 2026, compared with a net loss of $2.4 million in the prior-year quarter. Net loss per share was $0.36 on both a basic and diluted basis, in line with the consensus estimate of $0.36 and narrower than the $0.44 loss per share reported a year earlier. The company reported no revenue for the period.
Research and development expenses totaled $3.0 million, a 159% increase driven by higher nonclinical toxicology, drug substance, and clinical supply costs tied to PH-762. General and administrative expenses declined 9% to $1.2 million, reflecting lower outsourced consulting costs. Cash and cash equivalents stood at $10.6 million at quarter-end, down from $21.0 million at December 31, 2025.
Market Reaction and Sentiment
Because the reported per-share loss matched consensus, the quarterly financial figures themselves were unlikely to be a major surprise to investors. Instead, sentiment around this report has centered on execution of the PH-762 program. The completion of the first commercial-scale cGMP (current Good Manufacturing Practice) batch of drug substance and the submission of Phase 1b data to the FDA represent meaningful de-risking steps, but the declining cash position remains a key area of investor scrutiny. For a pre-revenue company, dilution risk and the timing of any future financing tend to weigh on sentiment as much as clinical progress.
What to Watch Going Forward
The most immediate catalyst is the FDA's response to the company's submission, expected by the end of November 2026. That feedback will help clarify the design and timing of the planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma (cSCC), which PHIO expects to initiate in the first quarter of 2027.
Investors should also monitor the company's cash runway. With $10.6 million in cash at quarter-end and R&D costs expected to keep rising, how the company funds the Phase 2b program will be a central question in the coming quarters.
Finally, watch for manufacturing and regulatory milestones. The successful cGMP batch of PH-762 drug substance supports clinical supply, but continued progress on chemistry, manufacturing, and controls (CMC) will be important as the company moves toward larger trials. These operational signals, rather than quarterly earnings alone, are likely to drive the stock's direction. From what I see, tracking these milestones closely will be key.
Using AI Tools for Biotech Analysis
In my research process, I often rely on Tickeron’s AI Screener to filter biotech names by technical patterns, fundamentals, and volatility metrics. It helps surface comparable setups and refine my view on relative strength without spending hours on manual scans. This kind of tool fits naturally into reviewing names like PHIO during earnings season.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for PHIO turns negative, indicating new downward trend
PHIO saw its Momentum Indicator move below the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 86 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PHIO turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PHIO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PHIO's RSI Oscillator exited the oversold zone, 37 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 66 of 72 cases where PHIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +4.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHIO advanced for three days, in 165 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
PHIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.739) is normal, around the industry mean (3.498). P/E Ratio (-0.621) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. PHIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of RNAi-based medical technologies and therapies
Industry Biotechnology
Advertisement